TIDMSYNC
RNS Number : 0286U
Syncona Limited
26 March 2019
Syncona Limited
Autolus hosts inaugural R&D day and updates on AUTO3
26 March 2019
Syncona Ltd, a leading healthcare company focused on founding,
building and funding global leaders in life science, notes the
announcement that its portfolio company, Autolus Therapeutics Plc
(NASDAQ: AUTL) (Autolus), is today hosting its inaugural R&D
day, with the event commencing at 8.00 am ET.
In the announcement, Autolus also provides an update on the
durability of the data from its AUTO3 programme in pediatric acute
lymphocytic leukemia (pALL), following its last update on the
programme at the American Society of Hematology Conference in
December 2018.
The announcement can be accessed on Autolus' investor website at
https://www.autolus.com/investor-relations and full text of the
announcement from Autolus is contained below.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 7611 2031
Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200
Copies of this press release and other corporate information can
be found on the company website at: www.synconaltd.com
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on
founding, building and funding global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in gene and cell therapy. We focus on
delivering dramatic efficacy for patients in areas of high unmet
need.
Autolus Therapeutics Unveils Expanded Next Generation Technology
and Pipeline and Provides Key Update on AUTO3 Program in Pediatric
ALL at R&D Day
Program and webcast - today, March 26, 2019 at 8:00 am ET
LONDON, UK, March 26, 2019 -- Autolus Therapeutics plc (Nasdaq:
AUTL), a clinical-stage biopharmaceutical company developing next
generation programmed T cell therapies for the treatment of cancer,
plans to present insights into the science behind tumor defense
mechanisms and the company's novel programmed T cell therapy
programs in development utilizing targeted, modular approaches
designed to address these mechanisms at its inaugural R&D Day,
today, in New York. In addition, the company plans to provide an
update on its AUTO3 program in pediatric acute lymphocytic leukemia
(pALL).
AUTO3 is the first dual-targeting CD19 and CD22 programmed T
cell therapy in development for both pALL and relapsed or
refractory diffuse large B-cell lymphoma (DLBCL). Updated data from
the ongoing AMELIA Phase 1/2 study in pALL demonstrates that 6 out
of 6 (100%) patients treated at the highest dose (>=3 x10(6)
/kg) achieved minimal residual disease (MRD) negative complete
responses (CR). Ongoing MRD negative CR remissions were noted in 4
out of 6 (67%) patients, with duration of up to 10 months as of
February 2019, the date of latest data follow-up. There have been
no reported CD19 or CD22 negative relapses in CAR T naïve patients.
Data also showed that AUTO3 continues to be generally well
tolerated with no >= Grade 3 CRS, no ICU admission, and no
pressors or critical care support for CRS required. The Phase 2
portion of the study is expected to start in the second half of
2019. For more information about this trial and the inclusion
criteria, visit www.ClinicalTrials.gov (NCT03289455).
"We are pleased to be hosting our inaugural R&D day,
providing a unique opportunity to present an in-depth overview of
our differentiated technology, multiple programs, market
opportunities and the significant pipeline progress we have
achieved, to date," stated Dr. Christian Itin, chairman and chief
executive officer of Autolus. "We expect to report data on all of
our active clinical programs at key medical conferences during
2019. Additionally, over the coming months, we expect to move two
programs into registrational trials and to progress our next
generation programs toward the clinic."
Today's R&D program will include the following
presentations:
-- Dr. Christian Itin, Chairman and Chief Executive Officer of Autolus - Welcome and Overview
-- Dr. Samir N. Khleif, Director of the Loop Immuno-Oncology Lab
and Biomedical Scholar and Professor of Oncology, Georgetown
University Medical Center - Immunotherapy, A Combinatorial Approach
for Success
-- Dr. Muhammad Al-Hajj, Senior Vice President, Translational
Sciences of Autolus - Translational Aspects of Tumor
Heterogeneity
-- Dr. Martin Pule, Chief Scientific Officer and Founder of
Autolus and Clinical Senior Lecturer at University College London
Cancer Institute - Tackling Solid Tumors: A Modular Approach to T
Cell Programming
-- Dr. Vijay Peddareddigari, Chief Medical Officer of Autolus -
Clinical Update: Current and Next Generation Programs
A live video webcast of the event will be available beginning at
8:00 am ET today on the Events section of Autolus' website:
https://www.autolus.com/investor-relations/news-events/events. An
archived replay will be available on the website for one year.
About AUTO3
AUTO3 is a programmed T cell therapy containing two independent
chimeric antigen receptors targeting CD19 and CD22 that have each
been independently optimized for single target activity. By
simultaneously targeting two B cell antigens, AUTO3 is designed to
minimize relapse due to single antigen loss in patients with B cell
malignancies. AUTO3 is currently being tested in two clinical
studies, AMELIA and ALEXANDER.
AMELIA is a single-arm, open label, multi-center Phase 1/2
clinical trial of AUTO3 in patients up to 24 years of age with
high-risk relapsed or refractory B-lineage. The trial is also
enrolling patients who previously received CD19 or CD22 targeting
therapies including other CAR T cell therapy. The purpose of this
study is to test the safety and efficacy, including the complete
remission rate or minimal residual disease (MRD) negative response,
of AUTO3. Autolus expects to enroll up to 54 patients in this
trial.
ALEXANDER is a single-arm, open label, multi-center Phase 1/2
clinical trial of AUTO3 in patients with relapsed or refractory
diffuse large B cell lymphoma (DLBCL). The purpose of this study is
to test the safety and efficacy, including the overall response
rate as per Lugano criteria, of AUTO3 followed by limited duration
of consolidation with anti-PD1 antibody. Autolus expects to enroll
up to 120 patients in this trial.
For more information about these trials and the inclusion
criteria, visit www.ClinicalTrials.gov.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of
cancer. Using a broad suite of proprietary and modular T cell
programming technologies, the company is engineering precisely
targeted, controlled and highly active T cell therapies that are
designed to better recognize cancer cells, break down their defense
mechanisms and eliminate these cells. Autolus has a pipeline of
product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PFUMMGZFGVFGLZM
(END) Dow Jones Newswires
March 26, 2019 06:18 ET (10:18 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024